| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| PRE 14A | A preliminary proxy statement providing notification matters to be brought to a vote |
Proxy Filings
|
||
| DEF 14A | Official notification to shareholders of matters to be brought to a vote ("Proxy") |
Proxy Filings
|
||
| DEFA14A | Additional proxy soliciting materials - definitive |
Proxy Filings
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
